A detailed history of Israel Englander (Millennium Management LLC) transactions in Exelixis, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 733,344 shares of EXEL stock, worth $25.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
733,344
Previous 385,686 90.14%
Holding current value
$25.4 Million
Previous $8.67 Million 119.59%
% of portfolio
0.01%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.96 - $27.6 $7.63 Million - $9.6 Million
347,658 Added 90.14%
733,344 $19 Million
Q2 2024

Aug 14, 2024

BUY
$20.34 - $23.73 $3.15 Million - $3.67 Million
154,707 Added 66.98%
385,686 $8.67 Million
Q1 2024

May 15, 2024

SELL
$20.17 - $23.93 $25.3 Million - $30 Million
-1,252,193 Reduced 84.43%
230,979 $5.48 Million
Q4 2023

Feb 14, 2024

SELL
$19.25 - $24.13 $3.48 Million - $4.36 Million
-180,816 Reduced 10.87%
1,483,172 $35.6 Million
Q2 2023

Aug 14, 2023

BUY
$18.17 - $20.48 $27.4 Million - $30.9 Million
1,506,354 Added 955.6%
1,663,988 $31.8 Million
Q1 2023

May 15, 2023

BUY
$16.3 - $19.41 $1.13 Million - $1.35 Million
69,378 Added 78.61%
157,634 $3.06 Million
Q4 2022

Feb 14, 2023

SELL
$14.96 - $17.39 $18.8 Million - $21.9 Million
-1,259,623 Reduced 93.45%
88,256 $1.42 Million
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $5.98 Million - $8.49 Million
381,334 Added 39.45%
1,347,879 $21.1 Million
Q2 2022

Aug 15, 2022

BUY
$17.44 - $23.16 $9.66 Million - $12.8 Million
553,905 Added 134.23%
966,545 $20.1 Million
Q1 2022

May 16, 2022

SELL
$17.03 - $22.67 $1.7 Million - $2.27 Million
-99,969 Reduced 19.5%
412,640 $9.36 Million
Q4 2021

Feb 14, 2022

BUY
$15.84 - $21.88 $1.95 Million - $2.7 Million
123,212 Added 31.64%
512,609 $9.37 Million
Q3 2021

Nov 15, 2021

BUY
$16.3 - $21.14 $1.94 Million - $2.52 Million
119,112 Added 44.07%
389,397 $8.23 Million
Q2 2021

Aug 16, 2021

SELL
$17.95 - $25.56 $9.67 Million - $13.8 Million
-538,901 Reduced 66.6%
270,285 $4.93 Million
Q1 2021

May 17, 2021

BUY
$20.53 - $25.22 $13.2 Million - $16.3 Million
644,560 Added 391.53%
809,186 $18.3 Million
Q4 2020

Feb 16, 2021

BUY
$18.39 - $24.8 $1.94 Million - $2.62 Million
105,591 Added 178.86%
164,626 $3.3 Million
Q3 2020

Nov 16, 2020

SELL
$20.67 - $26.94 $3.84 Million - $5 Million
-185,537 Reduced 75.86%
59,035 $1.44 Million
Q2 2020

Aug 14, 2020

SELL
$16.46 - $27.42 $8.9 Million - $14.8 Million
-540,451 Reduced 68.85%
244,572 $5.81 Million
Q1 2020

May 14, 2020

BUY
$14.46 - $21.8 $1.51 Million - $2.28 Million
104,475 Added 15.35%
785,023 $13.5 Million
Q4 2019

Feb 14, 2020

BUY
$15.15 - $18.89 $2.52 Million - $3.14 Million
166,229 Added 32.32%
680,548 $12 Million
Q3 2019

Nov 14, 2019

BUY
$17.68 - $22.65 $6 Million - $7.68 Million
339,285 Added 193.84%
514,319 $9.1 Million
Q2 2019

Aug 14, 2019

BUY
$18.93 - $24.75 $1.45 Million - $1.89 Million
76,558 Added 77.74%
175,034 $3.74 Million
Q1 2019

May 14, 2019

SELL
$19.6 - $24.76 $27 Million - $34.1 Million
-1,375,849 Reduced 93.32%
98,476 $2.34 Million
Q4 2018

Feb 14, 2019

SELL
$13.65 - $21.8 $9.94 Million - $15.9 Million
-728,515 Reduced 33.07%
1,474,325 $29 Million
Q3 2018

Nov 14, 2018

BUY
$15.87 - $22.4 $26.3 Million - $37.2 Million
1,659,077 Added 305.11%
2,202,840 $39 Million
Q2 2018

Aug 14, 2018

SELL
$18.56 - $22.45 $7.15 Million - $8.65 Million
-385,107 Reduced 41.46%
543,763 $11.7 Million
Q1 2018

May 15, 2018

SELL
$22.15 - $31.89 $5.11 Million - $7.36 Million
-230,918 Reduced 19.91%
928,870 $20.6 Million
Q4 2017

Feb 14, 2018

SELL
$24.23 - $30.93 $7.38 Million - $9.42 Million
-304,630 Reduced 20.8%
1,159,788 $35.3 Million
Q3 2017

Nov 14, 2017

BUY
$23.35 - $29.24 $34.2 Million - $42.8 Million
1,464,418
1,464,418 $35.5 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.2B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.